Central to these discoveries is the revelation of how CSCs co-opt tissue-resident niche cells to create metabolic milieus favorable to their maintenance and growth. For instance, in brain tumors, neurons, astrocytes, and microglia do not merely coexist with CSCs; rather, they engage in a sophisticated exchange of metabolic substrates, signaling molecules, and epigenetic cues. This reciprocal communication ties neuronal activity and glial metabolism to key metabolic processes, including cholesterol homeostasis, glutamine utilization, and the dynamic balance between glycolysis and oxidative phosphorylation (OXPHOS). Such an integration ensures the metabolic flexibility that underpins CSC plasticity and tumor progression within the neural milieu.

The nervous system, beyond passive structural roles, actively participates in reshaping tumor architectures. Tumors, particularly those harboring CSCs, have been shown to induce neurogenesis and extension of nerve fibers through mechanisms reminiscent of developmental neurogenesis. These processes are orchestrated by conserved signaling pathways such as NGF–Trk and Wnt, which are co-opted by CSCs alongside inflammatory mediators. Moreover, metabolic factors like dietary palmitic acid can induce epigenetic reprogramming in cancer cells, promoting secretion of molecules like galanin that activate intratumoral Schwann cells. The resultant remodeling of the extracellular matrix fosters environments conducive to metastasis, underscoring a complex nexus of neural, metabolic, and stromal interplay.

Delving deeper, neuron–tumor interactions transcend secreted factors. Tumor cells, including CSCs, can form functional synapse-like junctions with neurons, integrating into neural circuits. This electrical coupling effectively reinforces stem-like transcriptional programs within CSCs, potentiating their undifferentiated state and proliferative capacity. Concomitantly, neuronal activity-dependent neurotransmitter release, such as neuroligin-3, activates pivotal intracellular pathways like PI3K–mTOR, linking metabolic regulation to CSC expansion, particularly in glioblastoma. Indirect neural influences modify the tumor microenvironment by enhancing angiogenesis and facilitating perineural invasion, both of which correlate with aggressive clinical courses.

Glial components—astrocytes and microglia—constitute critical metabolic partners within the central nervous system’s tumor niche. Within glioblastomas, CSCs actively reprogram these glial cells, driving them from homeostatic functions into reactive states characterized by profound metabolic rewiring. Reactive astrocytes adapt key metabolic pathways to modulate nutrient availability, immune suppression, and promote tumor invasion, while microglia undergo shifts balancing glycolysis and mitochondrial function to maintain their activation states. Astrocyte-derived metabolites, such as glutamine and cholesterol, are strategically utilized by CSCs, facilitated by cholesterol efflux pathways involving ABCA1, to sustain tumor viability and stemness. These intricate metabolic exchanges also orchestrate immune cell recruitment and polarization, thus shaping tumor immunology in addition to metabolism.

Turning to hepatocellular carcinoma, the crosstalk between CSCs and hepatic niche cells encompasses parenchymal entities like hepatocytes and biliary endothelial cells, alongside stromal populations such as hepatic stellate cells (HSCs). Here, CSCs utilize extracellular vesicles loaded with regulatory microRNAs to reprogram HSCs into cancer-associated fibroblasts, fueling a fibrotic and angiogenic microenvironment. This specialization of the fibrotic niche is entrenched in metabolic reprogramming favoring redox homeostasis, amino acid anaplerosis, and extracellular matrix (ECM) stiffness. HSC-derived extracellular vesicles further enhance glycolytic flux and motility in CSCs, while biliary endothelial cells support CSC mitochondrial metabolism through glutamine dependency, highlighting the bidirectional nature of metabolite exchange in hepatic tumors.

In pancreatic ductal adenocarcinoma (PDAC), the metabolic symbiosis between CSCs and their predominant stromal cell partners, pancreatic stellate cells (PSCs) and cancer-associated fibroblasts (CAFs), is a hallmark of tumor resilience in nutrient-scarce microenvironments. CSCs exploit PSC-mediated autophagy-driven secretion of alanine and lactate to fuel mitochondrial oxidative processes, reducing their dependence on glucose and glutamine. This reverse Warburg effect establishes a metabolic niche wherein stromal glycolysis supports CSC OXPHOS, sustaining stemness and tumorigenicity. The ECM remodeling by PSCs enhances resistance to apoptosis via proline metabolism and redox balancing, further highlighting the sophisticated metabolic adaptations facilitating PDAC progression and immune evasion amidst chronic TME acidification.

Adipocytes, abundant in adipose-rich tumors such as breast, ovarian, and colorectal cancers, emerge as dynamic orchestrators of CSC metabolic plasticity. Tumor-associated adipocytes (TAAs) are transformed by CSC-derived inflammatory cues into metabolically active reservoirs that release free fatty acids, lipids, and adipokines to fuel CSC proliferation and survival. The uptake of lipids via transporters CD36 and FABP4 feeds into fatty acid oxidation, supplying ATP and maintaining redox equilibrium under glucose-limiting conditions. Furthermore, adipocyte-secreted proteases and signaling molecules activate stemness and EMT pathways like Wnt/β-catenin and AMPK, enhancing CSC renewal and therapeutic resistance. The interplay between obesity-induced systemic metabolic alterations and local adipocyte-driven cues intensifies these effects, positioning lipid metabolism as a crucial axis in CSC dynamics.

In the lung metastatic niche, alveolar epithelial cells, particularly alveolar type 2 (AT2) cells, have been implicated as critical parenchymal partners. AT2 cells display stem-like plasticity and engage in reciprocal signaling with metastatic CSCs, mediated through pathways including Wnt and Notch. This bidirectional communication supports tumor colonization and stemness enhancement. Metabolically, AT2 cells secrete lung-specific surfactant lipids such as dipalmitoylphosphatidylcholine, which, upon uptake by CSCs, may augment fatty acid oxidation and mitochondrial metabolism, bolstering survival in the lung microenvironment. Indirectly, AT2-derived factors modulate immune populations, thereby sustaining an immunosuppressive niche favorable to tumor persistence.

Beyond classical epithelial tumors, CSC metabolic adaptation extends into mesenchymal and systemic domains. In the bone microenvironment, tumor-originated lactate accumulation fosters osteoclast activation while suppressing osteoblast function, promoting an osteolytic niche supportive of metastatic tumor growth and CSC maintenance. Though direct interactions between muscle cells and CSCs are less established, skeletal muscle contributes substantially to systemic metabolic pools through the release of lactate, alanine, and glutamine during cachexia. These metabolites can augment tumor metabolic plasticity and stem-like traits indirectly, reflecting the interconnectedness of systemic metabolism and tumor biology.

Additional epithelial niches, such as in renal and intestinal cancers, also provide context-specific metabolic inputs. In renal cell carcinoma, metabolic rewiring favors a lactate shuttle with distinct transporter expression, supporting CSC oxidative metabolism. Moreover, pericyte-derived methionine has emerged as a niche metabolite promoting renal CSC stemness. Meanwhile, classic intestinal stem cell niches, characterized by Paneth and endothelial cells, encompass metabolic programs regulating reactive oxygen species and ketone signaling, which complement canonical growth factors to sustain CSC function and metabolic homeostasis.

Collectively, these insights underscore a unifying paradigm: CSC metabolic plasticity is not an autonomous trait but a product of bidirectional metabolic dialogue with tissue-resident and systemic cell types. This dialog integrates nutrient flux, metabolite exchange, and signaling cascades within specialized microenvironments, thereby enabling tumors to adapt, resist therapies, and metastasize across diverse organ contexts. Consequently, therapeutic strategies that target both CSC-intrinsic metabolism and the supporting organ-specific metabolic niches hold promise for enhancing cancer treatment efficacy. As the field advances, the convergence of metabolic biology, cellular crosstalk, and tumor ecology will likely redefine our approach to combating malignancies by disrupting these finely tuned metabolic partnerships.

Subject of Research: The metabolic plasticity and bidirectional crosstalk between cancer stem cells and organ-resident parenchymal and stromal cells.

Article Title: The Metabolic Plasticity of Cancer Stem Cells: Bidirectional Crosstalk with Organ-Resident Cells.

Article References: Jang, J., Gwak, M. & Kim, H. The metabolic plasticity of cancer stem cells: bidirectional crosstalk with organ-resident cells. Exp Mol Med (2026). https://doi.org/10.1038/s12276-026-01746-8

Image Credits: AI Generated

DOI: 09 June 2026

At the heart of this research lies the nuclear factor-kappa B (NF-κB) inhibitor alpha (IκBα), classically known for its cytoplasmic function in sequestering NF-κB and preventing its transcriptional activity. Alessio and colleagues reveal an unexpected mitochondrial localization of IκBα within cancer cells, where it assumes a radically different role by orchestrating metabolic rewiring that favors tumor growth and survival. This mitochondrial pool of IκBα appears to act as a pivotal regulator of mitochondrial bioenergetics and redox homeostasis, thereby enabling cancer cells to adapt dynamically to metabolic stress and enhance their proliferative capacity.

The authors employed a comprehensive suite of molecular biology techniques, metabolomics, and in vivo cancer models to dissect how mitochondrial IκBα modulates cancer metabolism. Their data demonstrate that mitochondrial IκBα enhances oxidative phosphorylation (OXPHOS) efficiency and stabilizes mitochondrial complex I assembly, resulting in increased ATP production and reduced reactive oxygen species (ROS) leakage. This bioenergetic optimization allows cancer cells to meet elevated energetic demands while mitigating oxidative damage, effectively fostering a more robust and resilient tumor phenotype.

Beyond metabolic control, Alessio et al. report that mitochondrial IκBα profoundly influences the tumor microenvironment, particularly by activating the endothelium. This activation promotes vascular remodeling and permeability, facilitating tumor angiogenesis and nutrient supply. Intriguingly, the study highlights that mitochondrial IκBα drives upregulation of endothelial adhesion molecules and pro-inflammatory cytokines, which collectively potentiate endothelial cell activation and recruitment of immune and stromal cells that support tumor progression.

A particularly novel finding of this study is the link between mitochondrial IκBα and cancer-associated thrombosis, a major cause of morbidity and mortality in cancer patients. The researchers show that mitochondrial IκBα enhances the pro-thrombotic phenotype of tumor endothelial cells by inducing expression of tissue factor and other coagulation modulators. This creates a microenvironment conducive to platelet aggregation and fibrin deposition, promoting thrombus formation that not only facilitates metastatic dissemination but also exacerbates cancer-associated coagulopathies.

The implications of these findings extend to clinical oncology, where targeting mitochondrial IκBα could represent a therapeutic avenue to disrupt metabolic plasticity, inhibit pathological endothelial activation, and reduce thrombosis in cancer patients. Alessio and colleagues suggest that therapies aimed at modulating mitochondrial IκBα function may confer dual benefits: direct suppression of tumor cell bioenergetics and mitigation of the pro-metastatic vascular niche.

Importantly, the study sheds light on the molecular underpinnings of metabolic heterogeneity within tumors. By delineating how mitochondrial IκBα selectively enhances OXPHOS, the authors challenge the traditional Warburg-centric model of cancer metabolism and underscore the nuanced metabolic adaptations cancer cells exploit to survive in hostile microenvironments.

The mechanistic insights provided by this work also highlight the intricate integration of mitochondrial signaling pathways with inflammatory and coagulation networks in cancer. Mitochondrial IκBα emerges as a central node that links metabolic control to immune modulation and vascular pathology, emphasizing the multifaceted nature of tumor progression.

Technically, the research leveraged CRISPR-Cas9 mediated gene editing to ablate mitochondrial IκBα specifically, enabling the dissection of its functions without perturbing cytoplasmic NF-κB inhibition. This precise approach allowed delineation of the unique contributions of mitochondrial IκBα, enhancing the specificity and relevance of the study.

Furthermore, metabolomic profiling unveiled that mitochondrial IκBα deficiency causes accumulation of tricarboxylic acid (TCA) cycle intermediates and a compensatory increase in glycolytic flux, highlighting adaptive metabolic shifts cancer cells undergo when deprived of mitochondrial IκBα’s regulatory influence.

The endothelial phenotypes observed were corroborated by in vivo models demonstrating reduced tumor angiogenesis and thrombus formation upon mitochondrial IκBα inhibition, suggesting that the mitochondrial regulator exerts systemic effects beyond cancer cells themselves.

This pioneering investigation opens numerous avenues for future research, including exploration of mitochondrial IκBα’s role across different cancer types and its potential interplay with other mitochondrial regulatory proteins. Moreover, understanding how mitochondrial IκBα expression is controlled at the transcriptional and post-translational levels may reveal additional therapeutic targets.

Overall, Alessio et al.’s work shifts paradigms by portraying mitochondrial IκBα not merely as a classical NF-κB inhibitor but a multifaceted mitochondrial orchestrator of cancer progression, integrating metabolic, vascular, and thrombotic dimensions into a coherent oncogenic program.

As cancer therapy increasingly embraces metabolic and microenvironmental targets, mitochondrial IκBα stands out as a promising biomolecular fulcrum to exploit, potentially transforming approaches to managing cancer progression and metastasis in the clinic.

Subject of Research:
Mitochondrial IκBα role in cancer progression through metabolic remodeling, endothelial activation, and thrombotic spread.

Article Title:
Mitochondrial IκBα fuels cancer progression through metabolic rewiring, endothelial activation, and thrombotic spread.

Article References:
Alessio, M., Petiti, J., Basile, R. et al. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03022-0

Image Credits: AI Generated

DOI:
https://doi.org/10.1038/s41420-026-03022-0

Keywords:
Mitochondrial IκBα, cancer metabolism, oxidative phosphorylation, endothelial activation, tumor microenvironment, cancer-associated thrombosis, metabolic rewiring, vascular remodeling, tissue factor, pro-thrombotic phenotype.